The peptides discussed by the advisory committee were formerly identified by the FDA as posing significant safety risks, and the vote to loosen restrictions has stirred controversy in medical circles.
“The biggest concern about these unregulated peptides is the lack of adequate human clinical evidence for the uses they are being marketed for,” says Rita Jew, PharmD, president at the Institute for Safe Medication Practices in San Francisco.
Here’s what the panel’s vote to expand peptide access could mean.
What Are Peptides?
“The formulation isn’t reviewed by the FDA before it reaches anyone,” says Sogol Ash, NMD, longevity director at ConciergeMD and Drip Hydration in Los Angeles. “Compounding pharmacies are overseen primarily by state boards, rather than under manufacturer-level federal oversight.”
Which Peptides Did the FDA Advisory Committee Review?
- Body Protection Compound-157 (BPC-157) This peptide is promoted for musculoskeletal healing, though most evidence comes from animal and laboratory studies — it is lacking large, high-quality human clinical trials. There is a hypothetical benefit for ulcerative colitis, the committee said. Many experts believe that there is not sufficient research to support the safe, effective use of BPC-157 in humans. “It has a substantial body of promising preclinical research, but that has not yet translated into robust clinical evidence in humans,” says Nora Khaldi, PhD, a Dublin-based molecular scientist and founder of Nuritas, a biotechnology company that uses AI to analyze peptides from plant sources for human health and wellness purposes.
- KPV (Lys-Pro-Val) Early lab and animal studies suggest that KPV may have skin and gut anti-inflammatory properties, but human clinical trials are limited. Even so, the committee discussed its potential for wound healing and inflammatory conditions like eczema and inflammatory bowel disease.
- TB-500 (Thymosin Beta-4) Evidence of TB-500’s benefits is limited to animal and preclinical research, with only a few well-designed human studies showing that the peptide could safely improve wound healing and promote sports recovery.
- MOTS-c This peptide is often marketed for weight loss, healthy aging, and exercise performance. The advisory committee focused on lab studies showing that MOTS-c has the potential to help treat obesity and osteoporosis, but there is very little evidence from human trials to support its safe, effective use. “MOTS-c has attracted considerable scientific interest because of its role in metabolism, and early human studies have begun, but there is currently insufficient evidence to support its use for obesity or osteoporosis,” Dr. Khaldi says.
- Semax While this peptide is commonly promoted for cognitive health and mood and is approved in Russia, there is only a paucity of research from Western scientists on its safety and effectiveness as a treatment for migraine and other neurological conditions.
- Epitalon This peptide is marketed for longevity and sleep, though interest in its potential cellular aging benefits stems largely from lab and animal research, with little rigorous human evidence that it slows aging or improves insomnia.
- Emideltide (Delta Sleep-Inducing Peptide, or DSIP) The advisory committee discussed the use of DSIP for chronic insomnia, narcolepsy, and opioid withdrawal. Many experts say that emideltide research has been limited and inconsistent for decades, with only small studies available and insufficient high-quality evidence that it effectively treats sleep disorders.
What Happens Next?
The panel’s recommendations do not mean that the FDA has approved the six peptides, nor does it make these drugs immediately available through compounding pharmacies. “The misreading I’d most want to head off is people treating this as an FDA seal of approval,” Ash says.
“It is important to note that a committee’s recommendation is not the same as FDA approval, and it does not mean these peptides have been proven safe or effective,” Jew says, noting that the panel’s recommendations are also not binding. “The FDA has the authority to overrule the recommendation if it deems that the evidence or public health considerations warrant a different decision.”
What the Advisory Committee Vote Could Mean for Peptide Access
However, experts caution that greater access should not be mistaken for scientific validation.
“A peptide becoming more widely available does not mean it has been shown to be safe and effective through the FDA drug approval process,” Khaldi says. “Those questions require a different level of scientific evidence.”
Ultimately, Khaldi says that good science is about asking questions and following the evidence: “Patients deserve treatments supported by robust human clinical research, transparent data, and high-quality manufacturing. That’s how we build trust in any new therapy.”
Read the full article here